An evaluation of tofenacine (elamol), a new drug for the treatment of depression.
D000275:Adjustment Disorders / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001593:Benzyl Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004987:Ethers / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005021:Ethylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000928:Antidepressive Agents; D001593:Benzyl Compounds; D004987:Ethers; D005021:Ethylamines